Alvotech Targets Chinese Biosimilars With Yangtze River Deal

Exclusive Partnership Covers Eight Biosimilar Candidates In China

Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.

Business_China
The deal offers access to China for Alvotech’s biosimilars portfolio • Source: Shutterstock

Yangtze River Pharmaceutical will market eight Alvotech biosimilars in China, under the terms of an exclusive deal that has just been agreed with the Alvogen sister company. The agreement involves the Alvotech & CCHT Biopharmaceutical joint venture between Alvotech and Changchun High & New Technology Industries – founded in March 2019 – and provides for biosimilar candidates to be manufactured in a new Chinese facility being constructed in Changchun.

“Through this partnership, a powerhouse has been created in one of the world’s largest biologics markets, designed to improve patient...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business